Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents
Appendix A: Key to Acronyms
(Last updated:3/27/2012; last reviewed:3/27/2012)
3TC lamivudine
3TC/ZDV lamivudine + zidovudine
ABC abacavir
ABC/3TC abacavir + lamivudine
ABC/3TC/ZDV abacavir + lamivudine + zidovudine
ACTG AIDS Clinical Trials Group
AIDS acquired immune deficiency syndrome
ALT alanine aminotransferase
APV amprenavir
ART antiretroviral therapy
ART-CC ART Cohort Collaboration
ARV antiretroviral
AST aspartate aminotransferase
ATV atazanavir
ATV/r atazanavir/ritonavir
AUC area under the curve
AV atrioventricular
AWP average wholesale price
AZT zidovudine
bDNA branched DNA
BID twice a day
BMD bone mineral density
BMI body mass index
BUN blood urea nitrogen
cap capsule
CAPD chronic ambulatory peritoneal dialysis
CBC complete blood count
CCB calcium channel blocker
CDC Centers for Disease Control and Prevention
CI confidence interval
Cmax maximum plasma concentration
CME continuing medical education
Cmin minimum plasma concentration
CMV cytomegalovirus
CNICS Centers for AIDS Research Network of Integrated Clinical Systems
CNS central nervous system
COC combined oral contraceptive
CPK creatine phosphokinase
CrCl creatinine clearance
CSF cerebrospinal fluid
CVD cardiovascular disease
CYP cytochrome P
d4T stavudine
D:A:D Data Collection on Adverse Events of Anti-HIV Drugs Study
ddC zalcitabine
ddI didanosine
DHHS Department of Health and Human Services
DILI drug-induced liver injury
DLV delavirdine
DM diabetes mellitus
D/M dual or mixed (tropic)
DMPA depot-medroxyprogesterone acetate
DOT directly observed therapy
DR delayed release
DRV darunavir
DRV/r darunavir/ritonavir
DXA dual-energy x-ray absorptiometry
EBV Epstein-Barr virus
EC enteric coated
ECG electrocardiogram
EFV efavirenz
EFV/FTC/TDF efavirenz + emtricitabine + tenofovir disoproxil fumarate
EI entry inhibitor
EIA enzyme immunoassay
ETR etravirine
FDA Food and Drug Administration
FI fusion inhibitor
FPV fosamprenavir
FPV/r fosamprenavir/ritonavir
FTC emtricitabine
FTC/TDF emtricitabine + tenofovir disoproxil fumarate
GAZT azidothymidine glucuronide
GHB gamma-hydroxybutyrate
GI gastrointestinal
HAD HIV-associated dementia
HAV hepatitis A virus
HBeAg hepatitis B e antigen
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCV hepatitis C virus
HD hemodialysis
HDL high-density lipoprotein
HELLP hemolysis, elevated liver enzymes, low platelet count (syndrome)
HHS Health and Human Services
HHV human herpes virus
HHV-8 human herpes virus-8
HIV human immunodeficiency virus
HIV-1 human immunodeficiency virus type 1
HIV-2 human immunodeficiency virus type 2
HIVAN HIV-associated nephropathy
HLA human leukocyte antigen
HPV human papilloma virus
HR hazard ratio
HRSA Health Resource Services Administration
hsCRP high sensitivity C-reactive protein
HSR hypersensitivity reaction
HTLV human T-cell leukemia virus
HTLV-1 human T-cell leukemia virus type 1
HTLV-2 human T-cell leukemia virus type 2
IAS-USA International AIDS Society-USA
IC inhibitory concentration
IDU injection drug user
IDV indinavir
IDV/r indinavir/ritonavir
IFN-γ interferon-gamma
IGRA interferon-gamma release assay
IL interleukin
IL-2 interleukin-2
IL-6 interleukin-6
IL-7 interleukin-7
IND investigational new drug
INH isoniazid
inj injection
INR international normalized ratio
INSTI integrase strand transfer inhibitor
IQ inhibitory quotient
IRB Institutional Review Board
IRIS immune reconstitution inflammatory syndrome
IUD intrauterine device
LDL low-density lipoprotein
LPV lopinavir
LPV/r lopinavir/ritonavir
LTBI latent tuberculosis infection
MAC Mycobacterium avium complex
MDMA methylenedioxymethamphetamine
mDOT modified directly observed therapy
MDR multidrug-resistant
MDRD modification of diet in renal disease (equation)
MHC major histocompatability complex
MI myocardial infarction
msec millisecond
MSM men who have sex with men
MTB Mycobacterium tuberculosis
MTCT mother-to-child transmission
MVC maraviroc
NA-ACCORD The North American AIDS Cohort Collaboration on Research and Design
NFV nelfinavir
NIH National Institutes of Health
NNRTI non-nucleoside reverse transcriptase inhibitor
NRTI nucleoside reverse transcriptase inhibitor
NVP nevirapine
OAR Office of AIDS Research
OARAC Office of AIDS Research Advisory Council
OI opportunistic infection
PAH pulmonary arterial hypertension
PCP Pneumocystis jiroveci pneumonia or Pneumocystis pneumonia
PDE5 phosphodiesterase type 5
PegIFN peginterferon
p-gp p-glycoprotein
PI protease inhibitor
PK pharmacokinetic
PMTCT prevention of mother-to-child transmission
PNS peripheral nervous system
PO by mouth
PPI proton pump inhibitor
PR protease (gene)
PT prothrombin time
QTc QT corrected for heart rate
RAL raltegravir
RBV ribavirin
RPV rilpivirine
RT reverse transcriptase (gene)
RT-PCR reverse transcriptase-polymerase chain reaction
RTV ritonavir
SJS Stevens-Johnson syndrome
soln solution
SPT skin patch test
SQV saquinavir
SQV/r saquinavir/ritonavir
STD sexually transmitted disease
SVR sustained virologic response
t½ half-life
T20 enfuvirtide
tab tablet
TAM thymidine analogue mutation
TB tuberculosis
TCA tricyclic antidepressant
TDF tenofovir disoproxil fumarate
TDF/FTC tenofovir/emtricitabine
TDM therapeutic drug monitoring
TEN toxic epidermal necrosis
TG triglyceride
TID three times daily
TPV tipranavir
TPV/r tipranavir/ritonavir
TST tuberculin skin test
UDP uridine diphosphate
UGT uridine diphosphate gluconyltransferase
UGT1A1 uridine diphosphate glucuronosyltransferase 1A1
ULN upper limit of normal
VPA valproic acid
WBC white blood cell
WHO World Health Organization
WITS Women and Infants Transmission Study
XDR extensively drug-resistant
XR extended release
ZDV zidovudine